Understand the source comparison
Best Peptides to Lose 30 Pounds Ranked: Clinical Comparison
This table ranks peptides by mean body weight reduction demonstrated in published randomized controlled trials. Rankings reflect clinical evidence. Not marketing claims or anecdotal reports. Tirzepatide Dual GIP/GLP-1 agonist 20.9% 72 weeks Weekly Strongest cl
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table ranks peptides by mean body weight reduction demonstrated in published randomized controlled trials. Rankings reflect clinical evidence. Not marketing claims or anecdotal reports.
- Tirzepatide
- Dual GIP/GLP-1 agonist
- 20.9%
- 72 weeks
- Weekly
- Strongest clinical evidence for 30+ pound reductions; GI side effects peak during titration but resolve in 4–8 weeks
- Semaglutide
- GLP-1 receptor agonist
- 14.9%
- 68 weeks
- Proven efficacy; appetite suppression mechanism well-characterized; FDA-approved for obesity
- Survodutide
- Triple GIP/GLP-1/glucagon agonist
- 15.7%
- 48 weeks
- Phase 2 only; promising data but lacks long-term safety profile
- Mazdutide
- Dual GLP-1/glucagon agonist
- 12.4%
- 24 weeks
- Investigational; adds thermogenic pathways GLP-1-only compounds miss
- Tesofensine
- Triple monoamine reuptake inhibitor
- 10.6%
- Daily oral
- No Phase 3 data; cardiovascular concerns halted prior development
- CJC-1295/Ipamorelin
- Growth hormone secretagogue
- 8–12%
- 16–24 weeks
- Daily subcutaneous
- Requires structured caloric deficit; no appetite suppression effect